Literature DB >> 12610812

A randomized, double blind, placebo controlled trial of a topical cream containing glucosamine sulfate, chondroitin sulfate, and camphor for osteoarthritis of the knee.

Marc Cohen1, Rory Wolfe, Trudy Mai, Daniel Lewis.   

Abstract

OBJECTIVE: To assess the ability of a topical preparation of glucosamine sulfate and chondroitin sulfate to reduce pain related to osteoarthritis (OA) of the knee.
METHODS: Sixty-three patients were randomized to receive either a topical glucosamine and chondroitin preparation or placebo to be used as required over an 8 week period. Efficacy was assessed using a visual analog scale (VAS) for pain as well as the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and the SF-36 questionnaire.
RESULTS: VAS scores indicated a greater mean reduction in pain for the glucosamine/chondroitin preparation group (mean change -3.4 cm, SD 2.6 cm) compared to the placebo group (mean change -1.6 cm, SD 2.7 cm) after 8 weeks. After 4 weeks the difference between active and placebo groups in their mean reduction from baseline was 1.2 (95% CI 0.1 to 2.4, p = 0.03) and after 8 weeks was 1.8 (95% CI for difference between groups, 0.6 to 2.9 cm; p = 0.002).
CONCLUSION: Topical application of glucosamine and chondroitin sulfate is effective in relieving the pain from OA of the knee and improvement is evident within 4 weeks.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12610812

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  20 in total

Review 1.  Targeted peripheral analgesics therapy for neuropathic pain.

Authors:  Charles E Argoff
Journal:  Curr Pain Headache Rep       Date:  2004-06

Review 2.  Topical treatments for pain.

Authors:  Charles E Argoff
Journal:  Curr Pain Headache Rep       Date:  2004-08

Review 3.  Chondroitin for osteoarthritis.

Authors:  Jasvinder A Singh; Shahrzad Noorbaloochi; Roderick MacDonald; Lara J Maxwell
Journal:  Cochrane Database Syst Rev       Date:  2015-01-28

4.  A randomized, placebo-controlled double-blinded comparative clinical study of five over-the-counter non-pharmacological topical analgesics for myofascial pain: single session findings.

Authors:  Daniel Avrahami; Amanda Hammond; Ceara Higgins; Howard Vernon
Journal:  Chiropr Man Therap       Date:  2012-03-21

Review 5.  Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.

Authors:  Jasvinder A Singh; Alomgir Hossain; Amy S Mudano; Elizabeth Tanjong Ghogomu; Maria E Suarez-Almazor; Rachelle Buchbinder; Lara J Maxwell; Peter Tugwell; George A Wells
Journal:  Cochrane Database Syst Rev       Date:  2017-05-08

Review 6.  Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis.

Authors:  Jasvinder A Singh; Alomgir Hossain; Elizabeth Tanjong Ghogomu; Ahmed Kotb; Robin Christensen; Amy S Mudano; Lara J Maxwell; Nipam P Shah; Peter Tugwell; George A Wells
Journal:  Cochrane Database Syst Rev       Date:  2016-05-13

Review 7.  The use of glucosamine therapy in osteoarthritis.

Authors:  Djamila Zerkak; Maxime Dougados
Journal:  Curr Pain Headache Rep       Date:  2004-12

Review 8.  The utility of nutraceuticals in the treatment of osteoarthritis.

Authors:  Tracy M Frech; Daniel O Clegg
Journal:  Curr Rheumatol Rep       Date:  2007-04       Impact factor: 4.592

Review 9.  Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.

Authors:  Jasvinder A Singh; Alomgir Hossain; Elizabeth Tanjong Ghogomu; Amy S Mudano; Lara J Maxwell; Rachelle Buchbinder; Maria Angeles Lopez-Olivo; Maria E Suarez-Almazor; Peter Tugwell; George A Wells
Journal:  Cochrane Database Syst Rev       Date:  2017-03-10

Review 10.  The use of glucosamine therapy in osteoarthritis.

Authors:  Djamila Zerkak; Maxime Dougados
Journal:  Curr Rheumatol Rep       Date:  2004-02       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.